High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients

Diabetologia

Volumn 57, Issue 6, 2014, Pages 1173-1181

  Gjesing, Anette P ^a   Hornbak, Malene ^a,b   Allin, Kristine H ^a   Ekstrøm, Claus T ^b   Urhammer, Søren A ^c   Eiberg, Hans ^d   Pedersen, Oluf ^a   Hansen, Torben ^a,e  

^a Capital Region   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Acute insulin response; Genetic correlation; Heritability; Tolbutamide modified frequently sampled intravenous glucose tolerance test; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; TOLBUTAMIDE;

ACUTE INSULIN RESPONSE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; FAMILY; FEMALE; GENETIC CORRELATION; GLUCOSE BLOOD LEVEL; HERITABILITY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; TOLBUTAMIDE MODIFIED FREQUENTLY SAMPLED INTRAVENOUS GLUCOSE TOLERANCE TEST; DRUG EFFECTS; GENOTYPE; GLUCOSE TOLERANCE TEST; METABOLISM; SECRETION (PROCESS);

DIABETES MELLITUS, TYPE 2; FAMILY; FEMALE; GENOTYPE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; TOLBUTAMIDE;

EID: 84901204547     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3207-y     Document Type: Article

References (40)

1. So HC, Gui AH, Cherny SS, Sham PC (2011) Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol 35:310-317
2. Watanabe RM, Valle T, Hauser ER et al (1999) Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. Hum Hered 49:159-168
3. Simonis-Bik AM, Eekhoff EM, de Moor MH et al (2009) Genetic influences on the insulin response of the beta cell to different secretagogues. Diabetologia 52:2570-2577
4. Rasmussen-Torvik LJ, Pankow JS, Jacobs DR et al (2007) Heritability and genetic correlations of insulin sensitivity measured by the euglycaemic clamp. Diabet Med 24:1286-1289
5. Lehtovirta M, Kaprio J, Forsblom C, Eriksson J, Tuomilehto J, Groop L (2000) Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins. Diabetologia 43:285-293
6. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE (1999) Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 84:1398-1403
7. Bergman RN, Zaccaro DJ, Watanabe RM et al (2003) Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes 52:2168-2174
8. Swen JJ, Guchelaar HJ, Baak-Pablo RF, Assendelft WJ, Wessels JA (2011) Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment. Pharmacogenet Genomics 21:461-468
9. Kirchheiner J, Bauer S, Meineke I et al (2002) Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101-109
10. Xu H, Murray M, McLachlan AJ (2009) Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Curr Drug Metab 10:643-658
11. Aquilante CL (2010) Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther 8:359-372
12. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
13. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME (1993) Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578-582
14. Faber OK, Markussen J, Naithani VK, Binder C (1976) Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin. Hoppe Seylers Z Physiol Chem 357:751-757
15. Faber OK, Binder C, Markussen J et al (1978) Characterization of seven C-peptide antisera. Diabetes 27(Suppl 1):170-177
16. Heding LG, Rasmussen SM (1975) Human C-peptide in normal and diabetic subjects. Diabetologia 11:201-206
17. Voight BF, Scott LJ, Steinthorsdottir V et al (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579-589
18. Almasy L, Blangero J (1998) Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 62:1198-1211
19. Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA (1998) Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 41:548-554
20. Breda E, Cobelli C (2001) Insulin secretion rate during glucose stimuli: alternative analyses of C-peptide data. Ann Biomed Eng 29:692-700
21. Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50:253-264
22. Kjems LL, Christiansen E, Volund A, Bergman RN, Madsbad S (2000) Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 49:580-588
23. Pacini G, Bergman RN (1986) MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23:113-122
24. Elbein SC, Sun J, Scroggin E, Teng K, Hasstedt SJ (2001) Role of common sequence variants in insulin secretion in familial type 2 diabetic kindreds: the sulfonylurea receptor, glucokinase, and hepatocyte nuclear factor 1alpha genes. Diabetes Care 24:472-478
25. Bergman RN (2005) Minimal model: perspective from 2005. Horm Res 64(Suppl 3):8-15
26. Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386
27. Visscher PM, Hill WG, Wray NR (2008) Heritability in the genomics era - concepts and misconceptions. Nat Rev Genet 9:255-266
28. Henquin JC (2004) Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 53(Suppl 3):S48-S58
29. Jonkers FC, Guiot Y, Rahier J, Henquin JC (2001) Tolbutamide stimulation of pancreatic beta-cells involves both cell recruitment and increase in the individual Ca(2+) response. Br J Pharmacol 133:575-585
30. Henquin JC (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-1760
31. 2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein. Proc Natl Acad Sci U S A 96:5539-5544
32. + channel-independent action. Diabetes 51(Suppl 1):S33-S36
33. Sesti G, Laratta E, Cardellini M et al (2006) The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 91:2334-2339
34. Holstein A, Hahn M, Stumvoll M, Kovacs P (2009) The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res 41:387-390
35. Hansen T, Echwald SM, Hansen L et al (1998) Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 47:598-605
36. Bort R, Martinez-Barbera JP, Beddington RS, Zaret KS (2004) Hex homeobox gene-dependent tissue positioning is required for organogenesis of the ventral pancreas. Development 131:797-806
37. Rosengren AH, Braun M, Mahdi T et al (2012) Reduced insulin exocytosis in human pancreatic beta-cells with gene variants linked to type 2 diabetes. Diabetes 61:1726-1733
38. Mourad NI, Nenquin M, Henquin JC (2011) Metabolic amplification of insulin secretion by glucose is independent of beta-cell microtubules. Am J Physiol Cell Physiol 300:C697-C706
39. Mourad NI, Nenquin M, Henquin JC (2010) Metabolic amplifying pathway increases both phases of insulin secretion independently of beta-cell actin microfilaments. Am J Physiol Cell Physiol 299:C389-C398
40. Chistiakov DA, Potapov VA, Smetanina SA, Bel'chikova LN, Suplotova LA, Nosikov VV (2011) The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel. Acta Diabetol 48:227-235